Q-omics provides the consensus-scored RPL26P3 profile across patient tissues and cancer cell-line models. RPL26P3 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RPL26P3 is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, RPL26P3 RNA expression shows 7,769 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight LIHC, LUSC, and HNSC as cancer lineages where RPL26P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL26P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL26P3 survival associations across molecular data types. RPL26P3 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL26P3 RNA expression–survival associations across cancer types. High RPL26P3 expression shows unfavorable associations in LIHC, STAD, KIRC and CESC, but favorable associations in LUSC and LUAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify LIHC as the clearest survival context for RPL26P3 RNA expression.
This table summarizes RPL26P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL26P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL26P3 shows higher tumor expression in LUSC, PRAD and STAD. The LUSC box plot shows higher RPL26P3 RNA expression in tumor versus normal tissue (log2 FC = +0.052, t-test p = .013).
This table shows molecular features associated with RPL26P3 in patient tissues and cancer cell lines. In patient samples, RPL26P3 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
